iRhythm Technologies 주식 (NASDAQ: IRTC)

에 대한 최신 뉴스 iRhythm Technologies (NASDAQ:IRTC) 주식

iRhythm Technologies

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

PonyAIFremont,,Ca,,Usa,-,Feb,28,,2020:,Autonomous,Driving,Startup

Equities

Mid Cap

News

Movers

CGON

FTDR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IRTC

KNSA

MTSR

PONY

PRDO

포니AI·힘스핸허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일) 오디티 테크, 멧세라, CG 온콜로지, 키닉사 파마슈티컬스, 킹소프트, 프론트도어, ATI, 퍼도세오, 아이리듬

포니AI·힘스앤허스 등 지난주 급등한 중형주 11종목 (4월 28일~5월 2일)

Trading Ideas

$BTC

IBRX

IONQ

WULF

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:IBRX)의 주식은 회사가 재발성 B-세포 비호지킨 림프종에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.

트럼프 미디어와 스트라이드는 지난주 최고 성과를 보여준 10개 중형주 중 일부 (10월 21일-10월 25일)

Bilibili_world

AMKR

BILI

BRFS

ITCI

OLLI

RKLB

TALO

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 빌리빌리(NASDAQ:BILI)의 주가는 지난주 &#39;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#39; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 21달러 가격 목표를 발표했다. 

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies Inc

WIIM

AXSM

Axsome Therapeutics shares are trading higher after the company announced a better-than-expected Q1 financial results.

Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92
SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:&nbsp;JNJ) today announced new data from the TREMFYA&#xAE; (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From TREMFYA Phase 3 QUASAR LTE Study In Adults With Moderately-To-Severely Active Ulcerative Colitis

Contracts

OPTT

Ocean Power Technologies Awarded Contract To Provide Unmanned Surface Vehicles To A Defense Customer, Terms Not Disclosed

B of A Securities analyst Rafe Jadrosich initiates coverage on Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Buy rating and announces Price Target of $82.

Price Target

Initiation

Analyst Ratings

B of A Securities Initiates Coverage On Meritage Homes with Buy Rating, Announces Price Target of $82

Howard Hughes Holdings shares are trading higher after the company announced an agreement with Pershing Square where it will make $900 million investment to acquire nine million newly issued shares.

- Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production -
- Findings offer a more detailed understanding of WTX-921's anti-inflammatory impact on the immune landscape in the inflamed colon -
WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a poster presentation further characterizing its conditionally-activated IL-10 INDUKINE molecule, WTX-921, at IMMUNOLOGY2025, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Honolulu, Hawaii.
Werewolf's findings are summarized in a poster titled, "Development of WTX-921, A Conditionally Active IL-10 INDUKINETM Molecule for the Treatment of Inflammatory Bowel Disease" (Board #1230). The results build on <a href="https://www.globenewswire.com/Tracker?data=g3R9bl2jWOGQ6q_IEzlhTI_bJwQlKxmLrxnuucnG2cnuZZa-KTgfBGUoQfM82aBi0X7xdlI9i8WRdELXjhLEkuRKKyIJ5n6D_QfbkyoiVgehR0jyS9li4S78-4rmHENMMAhBCwszXKvjgywzqhJR70o2_kyEqJF0J-KNJgQDWpMqqqVsYOBukyCIW1UWr0vKaxiKebE9Tbjw7FB_LWeU9Bv1TahaiwvidIG_JNbqIBc=">initial data presented</a> at the 2024 AAI Annual Meeting, which revealed preliminary proof-of-concept for its IL-10 INDUKINE molecule as a potential prodrug for IBD treatment.
The data corroborate the preferential cleavage of inflammatory disease linkers by inflamed human IBD tissue samples and reduced colitis in a murine IBD model as previously observed. New results also highlight WTX-921's effective masking of IL-10 via its optimized IL-10 blocking domain, which prevents the peripheral off-tissue pharmacodynamic effects of IL-10. The CDC estimates that 7 million people worldwide had IBD in 2024, and while clinical studies in IBD involving IL-10 have shown promise, they are consistently hampered by dose-dependent adverse events.

Biotech

General

HOWL

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing Its IL-10 INDUKINE Molecule, WTX-921, For The Treatment Of Inflammatory Bowel Disease At AAI Annual Meeting

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

MARA

MARA Announces Bitcoin Production And Mining Operation Updates For April 2025; Energized Hash Rate Grew 5.5% To 57.3 EH/s; Increased BTC Holdings To 48,237 BTC

TREMFYA&#xAE; subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis&nbsp;
Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA&#xAE; in Crohn's disease&nbsp;&nbsp;
SAN DIEGO, May 5, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA&#xAE; (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intravenous (IV) induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA&#xAE; is the first and only IL-23 inhibitor to demonstrate robust results with a fully SC regimen. These findings are among 24 abstracts highlighting the Company's research being&nbsp;presented at Digestive Disease Week (DDW) 2025.&nbsp;

Johnson & Johnson Announces New Data From Phase 3 ASTRO Study Evaluating TREMFYA Subcutaneous Induction Therapy In Adults With Ulcerative Colitis

B of A Securities analyst Taylor Morrison initiates coverage on Taylor Morrison Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMHC#NYSE">TMHC</a>) with a Buy rating and announces Price Target of $70.

TMHC

B of A Securities Initiates Coverage On Taylor Morrison Home with Buy Rating, Announces Price Target of $70

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) is down 10% over the past week but continues to attract bullish forecasts from traders, driven by its aggressive token burn rate and high <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">concentration in whale holdings</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001263</td>
<td>$7.4 billion</td>
<td>-2.7%</td>
<td>-9.7%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1705</td>
<td>$25.4 billion</td>
<td>-2.4%</td>
<td>-6.6%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.058064</td>
<td>$3.4 billion</td>
<td>-2%</td>
<td>-12.3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: In an X post on May 4, crypto trader Javon Marks <a href="https://x.com/JavonTM1/status/1918774008436125894?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1918774008436125894%7Ctwgr%5E485fe5b8b8fae6ec6d87bab9d10ffac3eb58f508%7Ctwcon%5Es1_c10&amp;ref_url=https%3A%2F%2Feditorial.benzinga.com%2Fwp-admin%2Fpost.php%3Faction%3Deditpost%3D901027">reiterated</a> his bold call for SHIB to hit $0.000081, a nearly 500% gain from current levels.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We maintain our $0.000081 breakout target for <a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> (Shiba Inu), projecting a nearly +500% uphill run to reach it&#8230; <a href="https://t.co/8OdILFYB5q">https://t.co/8OdILFYB5q</a> <a href="https://t.co/jTxSAGqiWA">pic.twitter.com/jTxSAGqiWA</a>
&mdash; JAVON&#x26a1;&#xFE0F;MARKS (@JavonTM1) <a href="https://twitter.com/JavonTM1/status/1918774008436125894?ref_src=twsrc%5Etfw">May 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trader Illusion X, <a href="https://x.com/illusionXcrypto/status/1919288659557196190">called</a> SHIB his "next big pick" for this cycle, projecting a 10x–15x move and urging accumulation.
Statistics: Shibburn data shows SHIB&#8217;s 24-hour burn rate jumping by 278.4%, with 2.2 million tokens incinerated in a single transaction just hours ago. 
The total weekly burn now stands at 313.95 million SHIB, a sign of consistent deflationary pressure that could boost price over time.
IntoTheBlock data shows Shiba Inu large transaction volume expanded by 8.9% while daily active addresses narrowed by 12.6% in a single day. 
Transactions greater than $100,000 increased from 38 to 43. SHIB whales still control 74% of the supply, underscoring continued long-term conviction among big holders.
Shiba Inu's Layer-2 network Shibarium has seen volatile usage, with daily transactions now at 3 million, bouncing back after a sharp 2-million drop. However, it has yet to reclaim its previous high of 4 million transactions.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45185999/shiba-inus-shibarium-is-booming-heres-whats-driving-the-54-transaction-surge">Shiba Inu&#8217;s Shibarium Is Booming — Here&#8217;s What&#8217;s Driving the 54% Transaction Surge</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Shiba Inu Drops 10% In 7 Days: What Is Going On?

TGTX

TG Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.

In a recent interview, Tesla CEO and billionaire Elon Musk shared what he hopes will eventually become his legacy: helping civilization progress.
Alongside his ambitious objectives for Tesla, SpaceX, and Neuralink, Musk stressed a mounting priority: developing artificial intelligence that is "maximally truth-seeking," which he called essential for AI safety.
What Happened: Speaking <a href="https://www.youtube.com/watch?v=1HcTXA951Mw">to</a> Lara Trump on Fox News, Musk listed a series of projects currently in development, including unsupervised self-driving cars that will make manually driven cars seem like "a horse", "robot buddies" that will assist humans in all kinds of tasks, space travel to enable the establishment of a "a self-sustaining city on Mars", and brain-computer interfaces that will "enable people who are blind to see" and "enable somebody who has a severed spinal column to walk again".
But he also issued a stark warning about AI: "The most important thing for AI safety is maximally truth-seeking AI… and if we don't, it will be very dangerous."
See Also: <a href="https://www.benzinga.com/markets/25/05/45186089/melinda-french-gates-takes-aim-at-elon-musks-doge-cuts-highlights-importance-of-philanthropy-and-government">Melinda French Gates Takes Aim at Elon Musk&#8217;s DOGE Cuts, Highlights Importance of Philanthropy and Government</a>
Why It Matters: Musk's statements come amid a series of controversies across sectors where he plays a central role.
NASA is about to see a <a href="https://www.benzinga.com/markets/25/05/45189017/nasa-prepares-for-6-billion-budget-cut-amid-shift-towards-elon-musks-mars-focused-initiatives">budget cut of $6 billion</a>, in line with Musk's Mars-focused aspirations, with multiple projects in space science, Earth science, and mission support divisions under threat.
On the other hand, <a href="https://www.benzinga.com/general/space/25/05/45163320/as-elon-musks-spacex-adds-28-starlinks-research-flags-climate-impact-from-deorbiting-satellites">a new study</a> showed that emissions from dying satellites may cause serious environmental damage, just as SpaceX added 28 more Starlink satellites to its burgeoning megaconstellation.
Meanwhile, despite Musk's comments about AI safety, <a href="https://www.benzinga.com/tech/25/04/45100013/elon-musks-xai-supercomputer-powering-grok-faces-human-rights-violation-allegations-in-memphis-over-pollutio">xAI&nbsp;is under fire in Memphis</a> for deploying several methane gas turbines allegedly without permits at its&nbsp;supercomputer site.&nbsp;
Previously, Musk had pledged to <a href="https://www.benzinga.com/personal-finance/25/04/45055568/elon-musk-said-hed-give-6-billion-to-end-world-hunger-if-the-un-could-explain-how-they-did-but-he-didnt-give-them-a-dime">donate $6 Billion to end world hunger</a> if the World Food Programme could explain how the money would be spent, but did not make good on his promise despite being provided with a detailed plan.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45163408/doge-not-as-effective-as-id-like-says-elon-musk-calls-reform-really-difficult-like-changing-direction-of-a-fleet-of-supertankers">DOGE Not &#8216;As Effective As I&#8217;d Like,&#8217; Says Elon Musk, Calls Reform &#8216;Really Difficult,&#8217; Like &#8216;Changing Direction Of A Fleet Of Supertankers&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Elon Musk Wants His Legacy To Be Advancing Civilization, Says Without 'Truth-Seeking AI,' The Future Could Be 'Dangerous'

CBL &amp; Associates (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBL#NYSE">CBL</a>) reported quarterly earnings of $0.27 per share. This is a 2800 percent increase over losses of $(0.01) per share from the same period last year. The company reported $141.77 million in sales this quarter. This is a 9.80 percent increase over sales of $129.12 million the same period last year.

Earnings

CBL & Associates Q1 EPS $0.27 Up From $(0.01) YoY, Sales $141.77M Up From $129.12M YoY

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Keefe, Bruyette &amp; Woods analyst Bose George downgraded the rating for Enact Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) from Outperform to Market Perform and maintained the price target of $39. Enact Holdings shares closed at $37.32 on Friday. <a href="https://www.benzinga.com/quote/ACT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert downgraded Plus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) from Buy to Hold. Plus Therapeutics shares closed at $0.6479 on Friday. <a href="https://www.benzinga.com/quote/PSTV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sheila Kahyaoglu downgraded the rating for Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) from Buy to Hold and cut the price target from $75 to $65. Parsons shares closed at $62.81 on Friday. <a href="https://www.benzinga.com/quote/PSN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Matthew Prisco downgraded Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) from Overweight to Neutral and lowered the price target from $250 to $135. Onto Innovation shares closed at $127.10 on Friday. <a href="https://www.benzinga.com/quote/ONTI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Macquarie analyst Paul Golding downgraded the rating for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from Outperform to Neutral and lowered the price target from $110 to $50. Block shares closed at $46.53 on Friday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying XYZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png" alt="" class="wp-image-901156" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/05081009/image-37.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

ONTO

PSTV

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

UBX1325 demonstrated vision gains that were comparable and statistically non-inferior to aflibercept at week 36 in a difficult-to-treat DME patient population&nbsp;
UBX1325 generally outperformed aflibercept in a pre-specified subgroup of patients entering the study with CST &lt;400 microns (60% of enrolled patients)
Company to explore strategic alternatives to advance UBX1325, Tie2/anti-VEGF bispecific, and Tie2 agonistic antibody assets and reduce operational cash burn
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced complete 36-week results from the Phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The Company previously disclosed 24-week and interim 36-week <a href="https://www.globenewswire.com/Tracker?data=diu3sRtqDoO3CddHHbn-1YIMcDhLulLaVJA8eviOj85ECqub7JGw6zYVthGHGN5dU1NfRG3nappEVwgUj97ZXPYxytFSZ6q5Knqo6QgGuFhtRzj1FjjvaTh8dVzlXEJEj_k2kAiqsuewPlBupiFb-57G6-mr_p2ShyKM1ta3lIZRjAmQ1VxbkKhKbTKVEKyOlv3t-JxfijwSdE745k9nJO0ELZZwbQPIxWDCfKIidMg=">results</a>&nbsp;from its ASPIRE trial, demonstrating that UBX1325 was non-inferior to aflibercept at most time points through 36 weeks, except for the average of weeks 20 and 24, the primary endpoint.

UNITY Biotechnology Announces Complete 36-Week Results From Phase 2b ASPIRE Clinical Trial Of Intravitreal UBX1325 In Patients With Diabetic Macular Edema

Anthropic co‑founder Jack Clark says Silicon Valley can dial down the alarms over China's latest AI darling, DeepSeek.
What Happened: Speaking on a Hill &amp; Valley Forum panel hosted by Lightspeed's Ravi Mhatre, Clark <a href="https://youtu.be/SsEoFDc1DIg?t=728">called</a> the buzz "perhaps a bit overblown."
He said DeepSeek's new model looks "six to eight months behind" frontier systems from U.S. labs and is hobbled chiefly by scarce computing power.
Anthropic ran the same national‑security red‑team tests it uses internally and found the Chinese model "significantly behind" its own, Clark added. "Neither one is yet a concern for the Pentagon — they're simply symptoms of progress we should track," he said.
What To Know: DeepSeek, founded in 2023 in Hangzhou, grabbed headlines by open‑sourcing its <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43253190/deepseek-ai-etfs-take-a-hard-hit-amid">R1 reasoning model</a>, claiming it cost just $5.6 million to build — a figure Wedbush analyst Dan Ives <a href="https://www.benzinga.com/tech/25/01/43296460/dan-ives-says-chinese-startup-deepseeks-6-million-ai-development-assertion-is-likely-a-fictional-story">has called</a> "likely a fictional story" given the billions the West spends on comparable AI research.
See also: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45187951/on-semiconductor-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">ON Semiconductor Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Google DeepMind chief Demis Hassabis recently labeled R1 "the best work to come out of China," <a href="https://www.benzinga.com/markets/25/02/43586484/google-deepmind-ceo-calls-deepseek-ai-best-work-from-china-but-says-hype-is-overblown-theres-no-actual-new-scientific-advance">but stressed</a> it offered no real scientific breakthrough.
Even Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), whose GPUs power most large models, framed DeepSeek as proof that compliant hardware can <a href="https://www.benzinga.com/markets/equities/25/01/43256425/nvidia-says-deepseek-an-illustration-of-how-new-ai-models-can-be-created-while-being-export-control-compliant-amid-600-billion-market-value-plunge">still yield</a> competitive systems under U.S. export curbs. Yet performance gaps persist. Benzinga's <a href="https://www.benzinga.com/markets/asia/25/04/44932492/is-deepseeks-threat-overrated-a-comprehensive-analysis">technical review</a> last month concluded DeepSeek's threat to U.S. dominance is "still overrated."
Why It Matters: Technical benchmarks show DeepSeek still trails U.S. rivals, yet Mark Zuckerberg <a href="https://www.benzinga.com/tech/25/04/45090992/mark-zuckerberg-warns-of-serious-disadvantage-as-chinas-data-center-blitz-could-let-deepseek-leapfrog-us-ai-labs">refuses to ignore</a> China's push to build AI infrastructure. He told the Dwarkesh Podcast last week that the United States must streamline &#8220;the ability to build data centers and produce energy" or risk falling behind.
Chinese tech giants, meanwhile, keep pouring money into AI and slashing prices to grab market share. Late last month Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) rolled out its <a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek">latest reasoning models</a>, Ernie 4.5 Turbo and Ernie X1 Turbo, while Alibaba Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and other peers unveiled <a href="https://www.benzinga.com/markets/emerging-markets/25/04/44796128/alibabas-quark-ai-surpasses-bytedances-doubao-with-150-million-monthly-users">developer‑friendly tools</a> that cost individuals just $1 a year. 
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/05/45188341/billionaire-mark-cuban-asks-if-small-businesses-be-ignored-after-trump-redirects-question-on-tariff-relief-for-little-businesses">Billionaire Mark Cuban Asks Should Small Businesses Be &#8216;Ignored&#8217; After Trump Redirects Question On Tariff Relief For &#8216;Little Businesses&#8217;</a>

BABA

BIDU

NVDA

Jeff Bezos‑Backed Anthropic Co‑Founder Says DeepSeek Hype Is 'A Bit Overblown,' Says R1 Trails US Labs By 'Six To Eight Months'

PTCT

PTC Therapeutics shares are trading lower. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington's disease patients.

Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) FY2025 Revenue expected to be more than $65.00M vs $64.55M Est

Guidance

Exagen FY2025  Revenue expected to be more than $65.00M vs $64.55M Est

SPRING Trial Data Presented at <a href="https://www.globenewswire.com/Tracker?data=Ne2ju-OepTyrrWVhZFCJlo26TbggIAgGyqP5Wxi_O2XZeBoMVCRR1vf61O2aaiXnNWkvFEld6vd6tvl44xGwThRj2zOkevICtGaqiLmTpFqvYFBGWeU_U-9wNR4NQz8zJS8U-aBE_BywLthIc83u3lOBCc3kPvkxKKeb5j8p3yWJT661NwIhrccdvH2Pv7aTCLuOxXNPb9xoabZVpvLnI_jYwx48YKAse5ZTwLkE1ioA4t1Tler5h5wYSl4V6vssoVbFW4FCvRL0dNXAFBCumVKgpfqjvmr87woinf2zCcG5H5zTTxWxWbuIKfXsU4ToB9S0IchfRtCptn3olntl59dEfzrPoziagRLSjwjSnbRxEMQcrZH8KXAg9nLqtwivRwrPOh99gJF1dhSvHlv5k14x58oAiWArLSnSNI7WqnOj13yOIJhjsoDP4mels3WB0rQ-IPagoV3hMmNacWvOi_Gc_-zekbzh-4mCUjZZh8xOftNml-OYctoxj9SZnrjzzABoHg_Y7U3HhivsGd8jWSBpIPuX71ey1jx__QAP3LjdLDGSYgUNFjewYkR0hI4BMv5pyA02syOyLkrMEqeCpu2tgsstSnpHth63UU9UJdatB5KvGCpZQaqi5ghk-ZfZ">Digestive Disease Week&#xAE;</a> 2025 Shows that Nebokitug at 15 and 48 Weeks&nbsp;of Treatment Is Well-Tolerated and Associated with Significant Improvements in Multiple Fibrotic and Inflammatory Biomarkers that Represent Slowing of Disease Progression
Confirms the Clinical Potential of Nebokitug As a First-in-Class Novel Treatment for PSC and Supports Advancement to Phase 3
TEL AVIV, Israel and SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=HoGcmrZgSma0nuJVaTbrlMKzQZf_J51TAnjViPuQaRW1rA4Kk3q06rHfGMsF2oHnTQxjG4qu7SDDL_eZZ2dMFu-hPMPqfhGM9Xri4DIX1bs=">Chemomab Therapeutics, Ltd</a>., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that data from the company's Phase 2 SPRING trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC)1 was presented in an oral Distinguished Abstract Plenary session at <a href="https://www.globenewswire.com/Tracker?data=Ne2ju-OepTyrrWVhZFCJlo26TbggIAgGyqP5Wxi_O2W2WavHXjySUwEqwN-ZE5dgLKIs7ftY0uY75H4h6RB2sht3eN8_kjTVt1Mgc5i9RzgCRrbvPr2srh9fY7VkD2TKPDZzlMOqQSjg16SeHUjSpTYHtkZin7RQvyhX63rPp5GGyk1klih0GKxVRiiwJoYsw-k0xo7NQXMsCq0ySGiW9nVvA04MrerrmFYm3ukdK8_gHvOCDOdHwj0fR3O-WTj1tUjJf8gkg7aZe6UJ4ILcy4JiTmdM-1b8eqsaJMDkZWd2JCTFUp9g__CIIrLy_90iXM9kk5jy-B85aIIlxieR31zS8fzIHrCTnif73I62UxBQP_9E1dBr90H75DVP5TqoPX-gGdk6IDEBDQcDNH3CPCcrDVMQfjr5svBEzLkhufXTLhFf_SGYF5Qr_ugRLQ9q3TGkOSeUjYUS7UAQyBg_HTun9Q1dhlXBadOJxTlahiw2cPpG5zJloB95vD-55P4xwuRspAU43Egxfl5I8Ma04iMwn-Ef7F3dEITt7xl-dI7pEAqFGC_v50u5relITDnpXmSils7Y3LnwL6Vt4pvGcerBvRbGMxY_mhebTWkGXSObZkt0FiwGlqVjFNOQONuu">Digestive Disease Week&#xAE;</a> (DDW 2025) in San Diego, California.

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

Chemomab Announces Presentation Of Nebokitug Phase 2 Clinical Data In Primary Sclerosing Cholangitis In Distinguished Plenary Session At DDW 2025

PRAX

Praxis Precision Medicines Highlights Developmental And Epileptic Encephalopathies Clinical Program Updates At Virtual Investor Event

Press Releases

iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results

iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of  Zio® Long-Term Continuous Monitoring for Arrhythmia Detection

Turing Medical Names Transformative Med Tech Leader Kevin King as President and Chief Executive Officer

iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability

iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025

Health Care

iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring

iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference

iRhythm Technologies Announces First Quarter 2025 Financial Results

iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection

Alphatec Holdings

AtriCure

Baxter Intl

Conmed

Enovis

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Integer Holdings Corporation Common Stock

Integer Holdings

LeMaitre Vascular

Masimo

NovoCure

Envista Holdings Corporation Common Stock

Envista Holdings

Omnicell

Penumbra

Insulet

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

Smith & Nephew

SS Innovations International Inc. - Common Stock

SS Innovations

Teleflex

TransMedics Group

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Canaccord Genuity

Wells Fargo

Baird

Needham

Goldman Sachs

지난주 가장 좋은 성과를 거든 중형주는 다음과 같다.
<ol>
<li>포니AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>)는 회사가 수익성에 가까워지고 있으며 <a href="https://www.benzinga.com//node/45049945" target="_blank" rel="noreferrer noopener">자율주행 시스템을 더 저렴하게 구축할 수 있다고 발표한 후</a> 주가가 48.36% 상승했다.</li>
<li>힘스 앤 헐스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) 주가는 회사가 노보 노디스크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>)와 협력하여 <a href="https://www.benzinga.com//node/45074872" target="_blank" rel="noreferrer noopener">위고비의 모든 용량 패키지를 플랫폼에서 제공하기로 발표</a>한 후 45.32% 급등했다. 뱅크오브아메리카 증권의 애널리스트는 <a href="https://www.benzinga.com/quote/hims/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 22달러에서 26달러로 상향 조정</a>했다.</li>
<li>오디티 테크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 가이던스를 상향 조정하며 <a href="https://www.benzinga.com//node/45111584" target="_blank" rel="noreferrer noopener">2분기 가이던스를 예상치를 초과하여 발표</a>한 후 42.96% 급등했다. 애널리스트들은 <a href="https://www.benzinga.com/quote/ODD/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>멧세라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) 주가는 지난 주 38.42% 상승했다.</li>
<li>CG 온콜로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) 주가는 회사가 크레토스티모진 그레나데노렙벡(cretostimogene grenadenorepvec) 단일요법 데이터를 미국 <a href="https://www.benzinga.com//node/45043205" target="_blank" rel="noreferrer noopener">비뇨기과학회 연례 회의에서 발표했다고 공개</a>한 후 29.86% 상승했다. 일부 애널리스트들은 커버리지를 개시하거나<a href="https://www.benzinga.com/quote/cgon/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>키닉사 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) 주가는 FY25 매출 가이던스를 <a href="https://www.benzinga.com//node/45063476" target="_blank" rel="noreferrer noopener">상향 조정</a>한 후 29.42% 상승했다.</li>
<li>킹소프트 클라우드 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) 주가는 27.34% 상승했다.</li>
<li>프론트도어(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) 주가는 회사가 기대 이상의 1분기 재무 결과를 발표하고 FY25 <a href="https://www.benzinga.com//node/45130988" target="_blank" rel="noreferrer noopener">매출 전망을 상향 조정</a>한 후 25.44% 상승했다.</li>
<li>ATI(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) 주가는 기대 이상의 분기 재무 결과를 보고하고 FY25 <a href="https://www.benzinga.com//node/45130989" target="_blank" rel="noreferrer noopener">조정 EPS 가이던스를 상향 조정한 후</a> 25.39% 상승했다.</li>
<li>퍼도세오 에듀케이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) 주가는 <a href="https://www.benzinga.com//node/45149554" target="_blank" rel="noreferrer noopener">1분기 결과를 발표</a>한 후 23.72% 상승했다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) 주가는 기대 이상의 1분기 결과를 발표하고 <a href="https://www.benzinga.com//node/45149802" target="_blank" rel="noreferrer noopener">FY25 매출 가이던스를 상향 조정</a>한 후 23.71% 급등했다.</li>
</ol>
사진 출처: Tada Images via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 10개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주식은 회사가 재발성 <a href="https://www.benzinga.com//node/41516867" target="_blank" rel="noreferrer noopener">B-세포 비호지킨 림프종</a>에 대한 CAR-NK 세포 치료제의 1상 임상 연구에서 첫 환자에게 투여했다고 발표한 후 49.86% 상승했다.
2. 스트라이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LRN#NYSE">LRN</a>)의 주식은 회사가 1분기 실적이 예상보다 좋게 나타났고, 2025 회계연도 및 2분기 <a href="https://www.benzinga.com//node/41487340" target="_blank" rel="noreferrer noopener">매출 가이던스도 예상치를 상회</a>했다고 발표한 후 41.43% 급등했다. 애널리스트들이 <a href="https://www.benzinga.com/quote/lrn/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
3. 퓨어사이클 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>)의 <a href="https://www.benzinga.com//node/41409452" target="_blank" rel="noreferrer noopener">주식은 32.21% 상승</a>했다.
4. 트럼프 미디어 앤 테크놀로지 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>)의 주식은 지난주에 31.68% 상승했다. 이 주식은 다가오는 미국 선거를 앞두고 변동성을 보였다.
5. 지커 인텔리전트 테크놀러지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>)의 주식은 29.31% 상승했다. 여러 미국 상장 중국 주식들이 인민은행이 <a href="https://www.benzinga.com//node/41547149" target="_blank" rel="noreferrer noopener">7,000억 위안</a> (약 983억 6천만 달러)를 은행 시스템에 주입하고 금리를 2.0%로 유지했다고 발표한 후 상승했다.
6. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 27.52% 상승했다.
7. 허크 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>)의 주식은 회사가 3분기 매출 실적이 예상보다 좋았고 2024 회계연도 장비 <a href="https://www.benzinga.com//node/41455862" target="_blank" rel="noreferrer noopener">임대 매출 성장 전망을 상향 조정</a>했다고 발표한 후 21.76% 상승했다.
8. 테라울프(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격 상승으로 18.59% 상승했다. 이 회사는 또한 4억 2,500만 달러를 전환사채로 조달할 것을 제안했다.
9. 아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/41462205" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">지오(Zio) AT 기기</a>의 이전 설계 변경과 관련된 510(k) 제출에 대해 FDA 승인을 받았다고 발표한 후 주가가 20.76% 상승했다.
10. 셀레스티카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>)의 주식은 회사가 3분기 실적이 예상보다 좋았고 4분기 매출 가이던스를 예상치를 상회한다고 발표한 후 19.99% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com//node/41523564" target="_blank" rel="noreferrer noopener">주가 목표</a>를 올렸다.
또한 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ED%85%8C%EC%8A%AC%EB%9D%BC%EC%99%80-%EB%A6%AC-%EC%98%A4%ED%86%A0%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%97%AC%EC%A4%80-10%EA%B0%9C-%EB%8C%80/" target="_blank" rel="noopener">테슬라와 리 오토는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%A0%9C%EB%89%B4%EC%9D%B8-%ED%8C%8C%EC%B8%A0-%EB%B0%8F-%ED%83%91%EB%B9%8C%EB%93%9C%EA%B0%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10/" target="_blank" rel="noopener">제뉴인 파츠 및 탑빌드가 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 21일-10월 25일)</a></li>
</ul>
Photo via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

iRhythm Technologies

뉴스

에 대한 최신 뉴스 iRhythm Technologies (NASDAQ:IRTC) 주식

일요일, 5월 04, 2025

월요일, 10월 28, 2024

월요일, 6월 24, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌